Giulia S, Pietro S, Alessandra V, et al. - In this exploratory retrospective review, researchers tested the safety and effectiveness of vismodegib treatment in patients with advanced basal cell carcinoma (BCC) and multiple comorbidities. In the current case series, 8 BCC patients (mean age was 80 ± 9.6) with multiple comorbidities were identified and involved. For elderly patients affected by multiple comorbidities and advanced BCC, vismodegib was shown to be a safe and well-tolerated treatment option with side effects of grade I and II and no changes in vital parameters, electrocardiography and echocardiogram.